Tocilizumab Beats Placebo in Depression Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Bristol ran a double‑blind, randomized trial of tocilizumab in 30 adults with moderate‑to‑severe depression who had not responded to standard antidepressants, lasting four weeks.
- Tocilizumab achieved a remission rate of 54% versus 31% for placebo, yielding a number‑needed‑to‑treat of 5, compared with an NNT of about 7 for typical SSRIs.
- Participants on tocilizumab reported greater improvements across depression severity, fatigue, state anxiety, and quality of life measures than those on placebo, despite limited statistical power.
- Golam Khandakar called the trial an “important milestone” as the first randomized test of IL‑6R blockade for depression and the first to use biomarker‑driven patient selection.
- Éimear Foley noted the findings provide early evidence that anti‑inflammatory immunotherapy can reduce depressive symptoms in patients who fail conventional treatments.
Why it matters: Patients with treatment‑resistant depression gain a new therapeutic option, while the pharma sector sees demand for IL‑6R blockers, potentially reshaping prescribing practices and reducing reliance on standard SSRIs.
